Daily Alert – 5/14/19
Five analysts have raised their earnings estimates for this biopharma in the past 30 days.
Read More
John McCamant Archives
4 Ways to Protect Your Portfolio
With things still volatile in the stock market, it's important to know how to protect your portfolio from big drops. Here are four ways to do it.
Read More
Wall Street’s Best Investments Daily Alert
Analysts expect this pharma to grow at more than 100% over the next five years.
Read More
5 Top Stock Picks for 2018
After beating the market handily in 2017, our Wall Street's Best experts are back with their top stock picks for 2018. Here are five of them.
Read More
Mix Up Your Investing Strategies and Boost Your Portfolio
Diversifying your portfolio doesn't just mean mixing up the sectors in which you invest, but also your investing strategies.
Read More
The Medicines Company (MDCO)
This drug maker hammered analysts’ earnings estimates, posting EPS of $2.62 last quarter, vs. the -$1.16 previously forecast. Analysts are forecasting double-digit growth rates for the rest of this year.
The Medicines Company (MDCO)From The Medical Technology Stock Letter
On its Q2 quarterly call, The Company...
Read More
Novavax, Inc. (NVAX)
This biotech missed analysts’ forecasts last quarter, losing $0.29 per share, compared to the estimated loss of $0.15. However, clinical trials are promising, and a takeover/partnership could soon be in the works. Two analysts have raised their 2017 earnings estimates in the past days.
Novavax,...
Read More
Top Stocks to Buy this Year
Every year, I ask our contributors to Wall Street’s Best Dividend Stocks and Wall Street’s Best Investments to select the one investment that they believe will be their biggest winner that year. And earlier this month, I published the winners in our special Picks...
Read More
Wall Street’s Best Investments Top Picks 2015
Congratulations to all of our contributors for their diligence and perseverance in finding winning stocks, and kudos to John McCamant of Medical Technology Stock Letter whose Top 2015 Pick led the way, with gains of 60.54%!
Wall Street’s Best Investments Top Picks 2015
Three of four...
Read More
A Hair-Raising Ride
The markets have certainly given us a hair-raising ride since last month. Although the Federal Reserve’s decision to bump up interest rates was already priced into the market, the headwinds of China sent global market exchanges into a tailspin.
Read More
Acadia Pharmaceuticals (ACAD)
New data for this drug company’s Parkinson’s disease treatment, its agreement with BASF Pharma who will manufacture and supply the active ingredient of NUPLAZID, and its undervalued price prompted Piper Jaffrey to upgrade the shares to “Overweight.”
Acadia Pharmaceuticals (ACAD) from Medical Technology Letter
Acadia (ACAD)...
Read More
Cellular Biomedicine Group Inc. (CBMG)
This drug company develops treatments for cancerous and degenerative diseases in Greater China. The listing of the shares was just upgraded from the NASDAQ Capital Market to the NASDAQ Global Market, which should bring additional exposure for the company.
Cellular Biomedicine Group Inc. (CBMG)
from Medical...
Read More
Most Recent Notable Mergers
In January of this year, KPMG estimated that 2015’s merger and acquisition activity would top the $1.62 trillion.
Read More
Pharmacyclics (PCYC)
As I mentioned in my blog post last week, here is an update on the PCYC/ABBV merger. Bottom line recommendation: hold onto your ABBV stock, post-merger.
Hold Pharmacyclics (PCYC)
from The Medical Technology Stock Letter
Updated from Investment Digest 759, July 23, 2014 Mid-Year Top Picks may...
Read More
Sangamo Biosciences Inc. (SGMO)
Analysts at JP Morgan just initiated coverage on this biotech with an “overweight” rating. And five of its scientists were also recognized by Thomson Reuters as being “Among Most Highly Cited Researchers Worldwide Of 2014”.
Sangamo Biosciences Inc. (SGMO)
from The Medical Technology Stock Letter
The call...
Read More
Pharmacyclics (PCYC)
Today’s 2014 Top Picks update is a biotech whose earnings estimates are trending up. This contributor has also increased his price target for the shares.
Pharmacyclics (PCYC)
from The Medical Technology Stock Letter
In January, Pharmacyclics (PCYC) released highly positive data from the RESONATE trial, the Phase...
Read More
Novavax (NVAX)
This biotech company just completed a successful Phase 2 clinical trial for its respiratory illness vaccine for women of childbearing age. Please note that shares of biotech companies are speculative in nature and should be allocated to a small percentage of your overall (NVAX)
from...
Read More
OncoGenex Pharmaceuticals (OGXI)
This biopharmaceutical company has two drug candidates in clinical development across multiple oncology therapeutic areas and a candidate in pre-clinical development.
OncoGenex’Pharmaceuticals (OGXI)
from The Medical Technology Stock Letter
OncoGenex Pharmaceuticals’ (OGXI ) custirsen could dominate second-line hormone resistant prostate cancer (HRPC) therapy. Medivation’s Xtandi has positive...
Read More
Investment Digest Top Picks from 2013 — A-D
It’s time for a look-back at our Top Picks from 2013—a year in which our contributors averaged a 31.27% return. I’ve broken the updates down alphabetically—into digestible sections—so that you can easily find the stocks in which you are interested. In each of alerts,...
Read More
Coronado Biosciences (CNDO)
Today we have one more mid-year update on a Top Pick for 2013, from The Medical Technology Stock Letter Analyst John McCamant. For new subscribers, his Top Pick is nearly buyable at current levels; a market pullback in the next day or two provide...
Read More